Project Grant R01GM153722
- Federal Project Grant Award Summary The Ohio State University received a $2,130,924 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025, through August 31, 2029. This award supports fundamental research into developmental regulation of oscillatory gene expression, specifically investigating the segmentation clock mechanism that controls somitogenesis—the...
- Federal Project Grant Award Summary The Ohio State University received a Project Grant award of $441,570 from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective May 1, 2026 through April 30, 2031. The award supports fundamental research investigating actin cytoskeleton organization and function in both health and disease contexts. The research project focuses on advancing understanding of how...
- Federal Project Grant Award Summary The Medical University of South Carolina received a $315,417 Project Grant from the National Institute of General Medical Sciences under the Biomedical Research and Research Training program (CFDA 93.859), effective May 1, 2026 through February 28, 2030. This award supports fundamental biomedical research investigating the molecular mechanisms of hypoxia-induced fibroblast migration during wound healing. The research aims to identify how low-oxygen...
- Federal Project Grant Award Summary The Ohio State University received a $410,893 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded March 1, 2026, with completion targeted for December 31, 2030. This award supports fundamental research in genomics-accelerated discovery and biosynthesis of phosphonic acid natural products (NPs). The research program aims to discover new microbial natural...
- Federal Project Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded The Ohio State University a Project Grant totaling $1,145,146 (awarded June 1, 2025; completion date March 31, 2030) under the Biomedical Research and Research Training program (CFDA 93.859). This grant funds advanced structural and dynamic research on large protein and protein-nucleic acid complexes relevant to human health and disease. The research integrates multidimensional magic-angle...
- Federal Grant Award Summary The Ohio State University received a $249,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective August 22, 2025, with a completion date of July 31, 2028. This research initiative investigates the role of ribonuclease L (RNase L), an innate immune enzyme activated during viral infections such as influenza A and hepatitis C, in cleaving host and viral...
- Award Summary The Ohio State University received a $416,726 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded on September 11, 2025, with a completion date of August 31, 2030. This award supports the development of mass spectrometry-based analytical technologies to enable chemical-specific measurement and analysis of cellular heterogeneity within organoids—three-dimensional cell...
- Federal Grant Award Summary The Ohio State University received a $375,898 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), with an award date of March 10, 2026, and a completion date of February 28, 2031. The research focuses on investigating oligosaccharide cross-feeding and competition in microbial communities, specifically examining how human gut bacteria modify dietary carbohydrate...
- Federal Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded The Ohio State University $498,000 under the Biomedical Research and Research Training program (CFDA 93.859) for a project grant beginning September 1, 2025, and concluding August 31, 2028. This award supports fundamental biomedical research investigating the molecular mechanisms that regulate protein synthesis during cell growth and division. The project addresses critical gaps in understanding how...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Ohio State University a $312,163 Project Grant effective July 3, 2025, through January 31, 2027, under the Allergy and Infectious Diseases Research program (CFDA 93.855). This award funds investigator-initiated research examining the role of the septin cytoskeleton in plasma membrane repair mechanisms. The research addresses a critical gap in understanding how mammalian cells...
The Ohio State University received a $303,082 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective April 1, 2026, with completion targeted for January 31, 2030. The award funds fundamental biomedical research investigating mast cell signaling mechanisms in wound healing and scar formation. Specifically, the project examines the role of Mas-Related G-Protein-Coupled Receptor B2 (MRGPRB2) signaling in connective tissue mast cells and its contribution to post-injury scar formation through immunoregulatory activities. The research deliverables include both in vivo and in vitro studies designed to elucidate novel wound-healing mechanisms toward achieving "scar-free regeneration" in humans. In vivo studies utilize genetically modified mouse models to assess the effects of manipulating MRGPRB2 signaling on skin scarring and regeneration, while mechanistically dissecting pro-inflammatory and pro-fibrotic properties in wound-healing animal models. In vitro studies employ skin wound-related cells derived from both murine and human sources to investigate MRGPRB2/X2-activated mast cell-driven immune cell polarization, endothelial-to-mesenchymal transition, and fibroblast proliferation and migration. The research addresses the significant clinical challenge of human skin scarring following trauma or surgery by exploring mechanisms that could inform effective therapeutic interventions.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $303.1k | 3/26/26 |